GH Research PLC

Healthcare · Biotechnology · Ireland

Last price 21.5 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.48B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company’s lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology tr...